Neogenomics (NEO) Depreciation and Depletion (2010 - 2026)

Neogenomics has reported Depreciation and Depletion for 17 years, with the latest figure at $8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion fell 6.26% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $35.5 million (down 7.98% YoY), and the FY2025 full-year result was $36.1 million, down 7.75% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $8.8 million, roughly flat from $8.8 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $9.9 million in Q1 2024, with the low at $8.4 million in Q1 2022.
• Historically, Depreciation and Depletion has averaged $9.2 million across 5 years, with a median of $9.3 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation and Depletion advanced 25.67% — and 2025, when it retreated 10.83%.
• Neogenomics' Depreciation and Depletion stood at $9.5 million in 2022, then grew by 1.06% to $9.6 million in 2023, then advanced by 2.6% to $9.8 million in 2024, then dropped by 10.83% to $8.8 million in 2025, then climbed by 0.19% to $8.8 million in 2026.
• The last three Depreciation and Depletion figures came in at $8.8 million (Q1 2026), $8.8 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.